Efficacy and Safety of CAR-T Cell Therapy in Advanced Gastrointestinal Tumors: A Systematic Review and Hierarchical Bayesian Meta-Analysis
Year: 2026
Type: preprint
Study designs: Systematic Review, Meta-Analysis
Abstract: Background: CAR-T cell therapy has shown transformative efficacy in hematologic malignancies, but its role in gastrointestinal solid tumors remains under investigation. Methods: Systematic review and meta-analysis of randomized and non-randomized clinical trials (PROSPERO: CRD42024629247). Searches were conducted in PubMed, Embase, LILACS, and Web of Science through November 2024. A Bayesian hierarchical binomial–logit model was used to pool proportions. Primary outcome was Objective Response Rate (ORR); secondary outcomes included cytokine release syndrome (CRS), ICANS, and grade ≥3 adverse events. Results: Thirty-nine studies comprising 658 participants were included. The global pooled ORR was 13.2% (95% CrI: 6.1%–21.8%), with substantial heterogeneity. GCC+CD19 (ORR 31.8%) and CLDN18.2 (ORR 21.8%) were the most promising targets. Any-grade CRS occurred in 40.8% of patients, with a 3.0% absolute risk of grade ≥3 events. Most studies presented serious or critical risk of bias and small sample sizes. Conclusions: CAR-T therapy shows initial effectiveness in gastrointestinal cancers, particularly for CLDN18.2 and GCC+CD19 targets. Well-powered controlled phase 2/3 trials are strongly needed. Clinical Trial Registration: PROSPERO CRD42024629247.
Source: Research Square
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7204847447
